Associated Papers
Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease.
von Scheidt M et al.
European Heart Journal, 2026
40900105 (PubMed )
Supplement: ehaf602_supplementary_data.pdf
Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort.
Regan JA et al.
Plos One, 2026
41666166 (PubMed )
Supplement: pone.0339491.s009.xlsx › S4_Table
Ancestry-dependent patterns of somatic mosaicism and clonal hematopoiesis mutations in over 125,000 individuals reveal distinct cancer associations.
Colin-Leitzinger C et al.
Human Genomics, 2025
41331781 (PubMed )
Supplement: 40246_2025_847_MOESM1_ESM.pdf
Clonal hematopoiesis in apparent treatment-resistant hypertension, insights from multiple medical centers and community-based cohorts.
Lv C et al.
Nature Aging, 2025
41286462 (PubMed )
Supplement: 43587_2025_1017_MOESM5_ESM.xlsx › Sheet3
Unveiling splicing disruptions due to common somatic variants in acute myeloid leukemia.
Morote-Faubel M et al.
Human Genomics, 2025
41189001 (PubMed )
Supplement: 40246_2025_842_MOESM1_ESM.pdf
A Vexing Diagnosis: ENT Presentation of Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome.
Wilson C et al.
Cureus, 2025
Clonal haematopoiesis associates with distinct cytometric changes of red blood cells and platelets.
Salzbrunn JB et al.
British Journal of Haematology, 2025
40754673 (PubMed )
Supplement: BJH-207-1085-s002.xlsx › CH_cohort
Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type.
Yang X et al.
Human Genomics, 2025
40877983 (PubMed )
Supplement: 40246_2025_792_MOESM2_ESM.xlsx › Table_S4
Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia.
Krizkova J et al.
Leukemia, 2025
40295826 (PubMed )
Supplement: 41375_2025_2609_MOESM1_ESM.pdf
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
Ikoma Y et al.
Leukemia, 2025
40259101 (PubMed )
Supplement: 41375_2025_2625_MOESM2_ESM.xlsx › Sheet5
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations.
Ni SC et al.
Blood Cancer Journal, 2025
40389402 (PubMed )
Supplement: 41408_2025_1287_MOESM2_ESM.xlsx › ___1
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.
Hiitola E et al.
Science Advances, 2025
40305610 (PubMed )
Supplement: sciadv.adt9846_tables_s1_to_s13.zip › adt9846_tables_s1_to_s13.xlsx › S3
Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis.
Boertjes EL et al.
Blood Advances, 2025
Comparative analysis of the Mexico City Prospective Study and the UK Biobank identifies ancestry-specific effects on clonal hematopoiesis.
Wen S et al.
Nature Genetics, 2025
39948438 (PubMed )
Supplement: 41588_2025_2085_MOESM4_ESM.xlsx › ST_5
Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies.
Platzbecker U et al.
Hemasphere, 2025
Clonal Hematopoiesis Associates with Prevalent and Incident Cardiometabolic Disease in High-Risk Individuals.
Regan JA et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
39867361 (PubMed )
Supplement: media-1.xlsx › Supplemental_Table_4
Impact of cytotoxic therapy on clonal hematopoiesis and myeloid neoplasms in breast cancer patients.
Kim H et al.
Medicine, 2024
39560556 (PubMed )
Supplement: medi-103-e40540-s001.xlsx › Table_S1
Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes.
Nead KT et al.
Blood Advances, 2024
38830141 (PubMed )
Supplement: BLOODA_ADV-2024-012929-mmc1.xlsx › STable_2
Unidirectional association of clonal hematopoiesis with atherosclerosis development.
Díez-Díez M et al.
Nature Medicine, 2024
39215150 (PubMed )
Supplement: 41591_2024_3213_MOESM3_ESM.xlsx › Supplementary_Table_2
Landscape of biallelic DNMT3A mutant myeloid neoplasms.
Kawashima N et al.
Journal of Hematology & Oncology, 2024
39334207 (PubMed )
Supplement: 13045_2024_1607_MOESM2_ESM.xlsx › Table_S8
Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience.
Blanco-Sánchez A et al.
Cancers, 2024
39335122 (PubMed )
Supplement: cancers-16-03149-s001.zip › cancers-3188970-supplementary.pdf
Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.
Kandarpa M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
38386293 (PubMed )
Supplement: ccr-23-0372_supplemental_table_2_suppst2.xlsx › Suppl._Table_2
Clonal hematopoiesis is associated with cardiovascular events in patients with stable coronary artery disease.
Dregoesc MI et al.
Iscience, 2024
38558938 (PubMed )
Supplement: mmc4.xlsx › Variant_characteristics
Outcome heterogeneity of TP53-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation.
Pasca S et al.
Haematologica, 2024
37731390 (PubMed )
Supplement: 2023_283886_PASCA_SUPPL.pdf
Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting.
Kubota Y et al.
Nature Communications, 2024
38418452 (PubMed )
Supplement: 41467_2024_46134_MOESM5_ESM.xlsx › Supplementary_Data_2
Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.
Moura PL et al.
Cancer Research, 2024
37921711 (PubMed )
Supplement: can-23-3038_data_s1_suppsd1.xlsx › Deidentified_clinical_data
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
McCarter JGW et al.
Blood Advances, 2023
37142255 (PubMed )
Supplement: BLOODA_ADV-2023-009675-mmc1.xlsx › supplemental_Table_2-Mutations
Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis.
Uddin MM et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
37732181 (PubMed )
Supplement: media-2.xlsx › Table_S3
Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.
Garrote M et al.
Cancers, 2023
37568719 (PubMed )
Supplement: cancers-15-03904-s001.zip › cancers-2478235-supplementary.pdf
Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment.
Stuckey R et al.
Cancers, 2023
37444494 (PubMed )
Supplement: cancers-15-03384-s001.zip › cancers-2437181-supplementary.pdf
The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia.
Chen X et al.
Cancer Medicine, 2023
Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.
Luque Paz D et al.
Hemasphere, 2023
37153874 (PubMed )
Supplement: hs9-7-e885-s001.xlsx › Supplemental_Table_S2
Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome.
El Khoury LY et al.
Clinical Epigenetics, 2023
37120552 (PubMed )
Supplement: 13148_2023_1471_MOESM1_ESM.xlsx › S3_Mutations_by_NGS
Molecular and immunophenotypic characterization of SMARCB1 (INI1) - deficient intrathoracic Neoplasms.
Haberecker M et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2022
35864317 (PubMed )
Supplement: 41379_2022_1133_MOESM1_ESM.pdf
Mediating and maintaining methylation while minimizing mutation: Recent advances on mammalian DNA methyltransferases.
Cheng X et al.
Current Opinion in Structural Biology, 2022
NPM1 exon 5 mutations in acute myeloid leukemia: Implications in diagnosis and minimal residual monitoring.
Wang P et al.
Ejhaem, 2022
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.
Kaisrlikova M et al.
Leukemia, 2022
35505182 (PubMed )
Supplement: 41375_2022_1584_MOESM2_ESM.xlsx › Mutations_214_LR-MDS
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
Adema V et al.
Ebiomedicine, 2022
35617825 (PubMed )
Supplement: mmc3.xlsx › Suppl_Table_3
The longitudinal dynamics and natural history of clonal haematopoiesis.
Fabre MA et al.
Nature, 2022
35650444 (PubMed )
Supplement: 41586_2022_4785_MOESM11_ESM.xlsx › historical_growth
Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.
González-López O et al.
Cancers, 2022
Genomic landscape of lung cancer in the young.
Ruiz R et al.
Frontiers in Oncology, 2022
36263208 (PubMed )
Supplement: DataSheet_2.pdf
Clonal cytogenetic abnormalities in donor-derived cells after sex mismatched allogeneic stem cell transplantation.
Toruner GA et al.
Cancer Genetics, 2021
Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors.
Riess JW et al.
Translational Oncology, 2021
34333275 (PubMed )
Supplement: mmc1.xlsx › Sheet2
Germline risk of clonal haematopoiesis.
Silver AJ et al.
Nature Reviews. Genetics, 2021
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial.
Ayala R et al.
Cancers, 2021
34070172 (PubMed )
Supplement: cancers-13-02458-s001.zip › cancers-1203671-supplementary › Table_S8.xlsx › Hoja2
Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients.
Stranneheim H et al.
Genome Medicine, 2021
33726816 (PubMed )
Supplement: 13073_2021_855_MOESM3_ESM.xlsx › Reported_genes_and_variants
1–50 of 65 papers
Select a paper to view details